TP53 and cancer: Indeed, their mutations (BRAFV600E and TP53) were found to be associated with an increased glycolysis, affecting the expression of glycolytic enzymes and glucose transporters [16,17,18], both features required to accomplish the metabolic and energetic demands of proliferating cancer cells [19].